ALK
ALK (ALK receptor tyrosine kinase, also known as CD246 and ALK1) is a neuronal cell-surface receptor tyrosine kinase that contributes to the genesis and differentiation of the nervous system. It was originally named anaplastic lymphoma kinase and is rearranged, mutated or amplified in several tumour types. Browse Assay Genie's current range of ALK research reagents below, or read on for the biology behind the target.
ALK is a neuronal receptor tyrosine kinase that is expressed essentially and transiently in specific regions of the central and peripheral nervous systems, where it plays an important role in the genesis and differentiation of the nervous system. In hypothalamic neurons it also acts as a key thinness protein: it controls energy expenditure as a negative regulator of white adipose tissue lipolysis and sympathetic tone, helping to fine-tune energy homeostasis. It may also regulate gastric epithelial differentiation.
Activation at the cell surface follows binding of the ligand ALKAL2, whereas ALKAL1 is not a potent physiological ligand. Ligand binding to the extracellular domain induces tyrosine kinase activity and activates the mitogen-activated protein kinase (MAPK) pathway. ALK phosphorylates almost exclusively the first tyrosine of the Y-x-x-x-Y-Y motif, and induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as MAPK1/ERK2 and MAPK3/ERK1. Pleiotrophin (PTN) and midkine (MDK) may also regulate ALK. PTN binding drives MAPK signalling important for its anti-apoptotic effects and for cell proliferation, while MDK binding induces IRS1 phosphorylation and activates MAPKs and PI3-kinase. ALK also drives NF-kappa-B activation, probably through IRS1 and AKT, which is essential for the autocrine growth and survival signalling of MDK.
The ALK gene encodes a protein with an extracellular domain, a single-pass transmembrane region and an intracellular kinase domain. It belongs to the Tyr protein kinase family and the insulin receptor subfamily, and sits in the ALK and LTK receptor tyrosine kinase family and the CD molecules group. Chromosomal rearrangements are the most common alterations in anaplastic large cell lymphoma, neuroblastoma and non-small cell lung cancer, producing fusion genes with partners such as EML4, RANBP2, ATIC, TFG, NPM1, SQSTM1, KIF5B, CLTC, TPM4 and MSN.
The ALK gene is rearranged, mutated or amplified in anaplastic large cell lymphoma, neuroblastoma and non-small cell lung cancer, making it central to fusion-driven tumourigenesis.
ALK is transiently expressed in specific regions of the central and peripheral nervous systems and contributes to the genesis and differentiation of the nervous system.
In hypothalamic neurons ALK limits white adipose tissue lipolysis and sympathetic tone, supporting studies of resistance to weight gain.
ALK activation by ALKAL2, PTN or MDK engages MAPK, PI3-kinase and NF-kappa-B signalling through substrates such as IRS1, FRS2 and SHC1.
ALK is a receptor tyrosine kinase at the cell membrane. After ligand binding, notably ALKAL2, it activates its kinase domain and the MAPK pathway. It supports the genesis and differentiation of the nervous system and, in hypothalamic neurons, helps regulate energy expenditure and resistance to weight gain.
ALK stands for ALK receptor tyrosine kinase. Aliases include CD246 and ALK1, and earlier names were anaplastic lymphoma kinase (Ki-1) and anaplastic lymphoma receptor tyrosine kinase. The UniProt protein name is ALK tyrosine kinase receptor.
ALK is rearranged, mutated or amplified in anaplastic large cell lymphomas, neuroblastoma and non-small cell lung cancer, often as fusion genes such as EML4-ALK or NPM1-ALK. The mouse ortholog is Alk. Check the datasheet of any product for its validated reactivity.
Related targets with products at Assay Genie, including other proteins whose names begin with ALK.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9UM73; product specifications from Assay Genie datasheets.